Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
January 23, 2024 11:13 AM EST
Deals

No­vo Nordisk con­tin­ues to stack obe­si­ty pipeline, this time with Swiss ze­brafish biotech

Lei Lei Wu

News Reporter

No­vo Nordisk li­censed an ex­per­i­men­tal obe­si­ty pill from Er­a­Cal Ther­a­peu­tics in a deal worth €235 mil­lion, or rough­ly $255 mil­lion, as it hunts for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times